Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rescue Helicobacter pylori eradication with rifabutin, sitafloxacin, and vonoprazan
jRCTs031230735Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rifabutin, sitafloxacin and vonoprazan in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Apr 2024; status: active, not recruiting.
02
Drugs
rifabutinsitafloxacinvonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031230735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230735.